Metastatic Colorectal Cancers Completed Phase 3 Trials for Bevacizumab (DB00112)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00252564Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal CancerTreatment
NCT01640405Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral CellsTreatment
NCT03288987A Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (AryoGen Pharmed) Compared With Bevacizumab (AvastinĀ®) in Metastatic Colorectal CancerTreatment
NCT01878422Sequential Treatment Strategy for Metastatic Colorectal CancerTreatment
NCT00911170PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation StudySupportive Care
NCT00598156Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- TarcevaTreatment